PalmGen Science selects non-clinical projects for national new drug development projects 'MRI liver-specific contrast agents'
Nov 26, 2024
FarmGenScience (CEO Park Hee-deok, Kim Hye-yeon) announced on the 26th that it has signed a research and development agreement with the National New Drug Development Project Group (Director Park Young-min) for MRI liver-specific contrast agent 'RD1303.
The National New Drug Development Project aims to strengthen the global competitiveness of the domestic pharmaceutical and bio industries, and is a government-supported project that supports research funds for the entire cycle of new drug development. PalmGen Science was selected as the national new drug development project in 2022 and successfully completed the derivation of MRI liver-specific contrast agent new drug candidates.
With the selection of this research project, PalmGen Science received two years of non-clinical research and development support from the National New Drug Development Project Group for the approval of RD1303's phase 1 clinical trial plan (IND).
The MRI liver-specific contrast agent being developed by PalmGen Science is a gadolinium-based macrocyclic liver-specific contrast agent that improves structural stability compared to existing linear liver contrast agents, and can minimize fatal systemic side effects and residual problems in the body of gadolinium ions.
RD1303 is an MRI liver-specific contrast agent that can increase the accuracy of liver cancer diagnosis by increasing the contrast between normal liver tissue and cancer tissue by selectively being absorbed by transporters present in normal liver tissue.
The company has recently completed Japanese patent registration following Australia last year, and has applied for patents in eight countries around the world, including the United States. In addition, it was published in the Journal of Medical Chemistry, a leading journal in the field of pharmaceutical chemistry, and its academic excellence was recognized.
The global MRI contrast medium market is a large market that is expected to reach about 3.2 trillion won by 2031, especially amid the global trend of strengthening drug safety and emphasizing the importance of prevention and early diagnosis rather than treatment.
The National New Drug Development Project aims to strengthen the global competitiveness of the domestic pharmaceutical and bio industries, and is a government-supported project that supports research funds for the entire cycle of new drug development. PalmGen Science was selected as the national new drug development project in 2022 and successfully completed the derivation of MRI liver-specific contrast agent new drug candidates.
With the selection of this research project, PalmGen Science received two years of non-clinical research and development support from the National New Drug Development Project Group for the approval of RD1303's phase 1 clinical trial plan (IND).
The MRI liver-specific contrast agent being developed by PalmGen Science is a gadolinium-based macrocyclic liver-specific contrast agent that improves structural stability compared to existing linear liver contrast agents, and can minimize fatal systemic side effects and residual problems in the body of gadolinium ions.
RD1303 is an MRI liver-specific contrast agent that can increase the accuracy of liver cancer diagnosis by increasing the contrast between normal liver tissue and cancer tissue by selectively being absorbed by transporters present in normal liver tissue.
The company has recently completed Japanese patent registration following Australia last year, and has applied for patents in eight countries around the world, including the United States. In addition, it was published in the Journal of Medical Chemistry, a leading journal in the field of pharmaceutical chemistry, and its academic excellence was recognized.
The global MRI contrast medium market is a large market that is expected to reach about 3.2 trillion won by 2031, especially amid the global trend of strengthening drug safety and emphasizing the importance of prevention and early diagnosis rather than treatment.
|
bellho@sportschosun.com
